Startseite A single crystal study on tert-butyl-4-((4-(4-bromo-2-fluorophenylamino)-6-methoxyquinazolin-7-yloxy)methyl)piperidine-1-carboxylate, C26H30BrFN4O4
Artikel Open Access

A single crystal study on tert-butyl-4-((4-(4-bromo-2-fluorophenylamino)-6-methoxyquinazolin-7-yloxy)methyl)piperidine-1-carboxylate, C26H30BrFN4O4

  • Kai Wang EMAIL logo und Qiang Chen
Veröffentlicht/Copyright: 14. Juli 2017

Abstract

C26H30BrFN4O4, monoclinic, P21/c (no. 14), a = 10.9035(6) Å, b = 8.0936(6) Å, c = 29.429(2) Å, β = 98.136(2)°, V =2570.9(3) Å3, Z = 4, Rgt(F) = 0.0434, wRref(F2) = 0.0897, T = 173(2) K.

CCDC no.:: 1558751

The crystal structure is shown in the figure. Table 1 contains details on crystal structure and measurement conditions. Table 2 lists the atoms with their coordinates and displacement parameters.

Table 1

Data collection and handling.

Crystal:Colourless column
Size:0.19 × 0.11 × 0.08 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:16.5 cm−1
Diffractometer, scan mode:CAD4, ω-scans
2θmax, completeness:50.78°, >98%
N(hkl)measured, N(hkl)unique, Rint:18757, 4643, 0.078
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 3190
N(param)refined:332
Programs:CAD4 [1], XCAD4 [2], SHELX [3], PLATON [4]
Table 2

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
Br1−0.74155(3)0.56733(5)0.382867(12)0.03775(13)
C10.0090(3)0.3728(4)0.44747(10)0.0248(8)
H10.03260.43050.42200.030*
C2−0.1479(2)0.2825(4)0.48415(10)0.0199(7)
C3−0.0605(2)0.2049(4)0.51821(10)0.0176(7)
C40.0648(3)0.2267(4)0.51284(10)0.0201(7)
C50.1581(3)0.1568(4)0.54559(10)0.0216(7)
H50.24280.17280.54240.026*
C60.1280(2)0.0675(4)0.58140(10)0.0195(7)
C70.0001(3)0.0429(4)0.58647(10)0.0198(7)
C8−0.0900(3)0.1110(4)0.55562(10)0.0205(7)
H8−0.17440.09520.55920.025*
C9−0.5941(3)0.4738(4)0.41522(10)0.0221(8)
C10−0.6013(3)0.3723(4)0.45233(10)0.0234(8)
H10−0.67820.34740.46240.028*
C11−0.4914(3)0.3089(4)0.47392(10)0.0224(7)
C12−0.3756(2)0.3422(4)0.46127(10)0.0204(7)
C13−0.3735(3)0.4459(4)0.42347(10)0.0244(7)
H13−0.29660.47260.41360.029*
C14−0.4827(3)0.5104(4)0.40020(11)0.0246(8)
H14−0.48080.57920.37410.029*
C150.3381(2)0.0172(4)0.61442(10)0.0233(8)
H15A0.36030.13530.61880.028*
H15B0.3618−0.02020.58480.028*
C160.6061(3)−0.1935(4)0.69183(10)0.0251(8)
H16A0.5781−0.30930.68700.030*
H16B0.6970−0.19060.69210.030*
C170.5431(2)−0.0859(4)0.65289(10)0.0220(7)
H17A0.5612−0.12950.62310.026*
H17B0.57570.02820.65640.026*
C180.4032(2)−0.0847(4)0.65348(10)0.0199(7)
H180.3727−0.20100.64930.024*
C190.3761(3)−0.0244(4)0.70036(10)0.0223(8)
H19A0.40260.09220.70480.027*
H19B0.2857−0.02950.70130.027*
C200.4434(2)−0.1292(4)0.73915(10)0.0246(8)
H20A0.4302−0.08180.76910.030*
H20B0.4094−0.24280.73720.030*
C210.6592(3)−0.0862(4)0.77188(10)0.0217(7)
C220.8817(3)−0.0395(4)0.79543(10)0.0238(8)
C230.8677(3)0.1345(5)0.81255(12)0.0359(9)
H23A0.84440.20830.78640.054*
H23B0.94640.17120.82980.054*
H23C0.80310.13680.83260.054*
C240.9882(3)−0.0511(5)0.76730(11)0.0319(8)
H24A0.9942−0.16440.75610.048*
H24B1.0658−0.02100.78650.048*
H24C0.97310.02470.74110.048*
C250.8962(3)−0.1658(5)0.83382(12)0.0393(10)
H25A0.8292−0.15200.85250.059*
H25B0.9762−0.14980.85310.059*
H25C0.8925−0.27730.82070.059*
C26−0.1428(3)−0.0798(5)0.63013(12)0.0359(9)
H26A−0.18340.02560.63480.054*
H26B−0.1441−0.15010.65720.054*
H26C−0.1868−0.13530.60300.054*
F1−0.49413(14)0.2067(3)0.51079(6)0.0338(5)
N10.1000(2)0.3128(3)0.47649(8)0.0239(6)
N2−0.1146(2)0.3637(3)0.44897(8)0.0232(6)
N3−0.2727(2)0.2710(4)0.48780(9)0.0251(6)
H3A−0.289(3)0.221(4)0.5115(8)0.030*
N40.5760(2)−0.1341(3)0.73596(8)0.0234(6)
O10.20758(17)−0.0061(3)0.61485(7)0.0245(5)
O20.77538(17)−0.0854(3)0.76081(7)0.0248(5)
O30.63249(18)−0.0475(3)0.80921(7)0.0307(6)
O4−0.01761(17)−0.0503(3)0.62350(7)0.0264(5)

Source of material

The title compound is easily available by a known literature synthesis [5]. In a typical reaction 0.2 g of the title compound was dissolved in 6 mL methanol. Evaporation at room temperature yielded colourless crystals of tert-butyl 4-((4-(4-bromo-2-fluorophenylamino)-6-methoxyquinazolin-7-yloxy)methyl)piperidine-1-carboxylate.

Experimental details

The hydrogen atoms (except H3a) were placed on calculated positions with the program SHELXL (AFIX 43, 23, 13 or 137 option) [3].

Discussion

The title compound is a very important intermediate in the production process of Vandetanib. Vandetanib (trade name Caprelsa, Astra Zeneca) is an anti-cancer drug used for the treatment of certain tumours of the thyroid gland [6]. Its pharmacological property is that of a kinase inhibitor for a number of cell receptors, mainly the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase. The compound reported here, tert-butyl-4-((4-(4-bromo-2-fluorophenylamino)-6-methoxyquinazolin-7-yloxy)methyl)piperidine-1-carboxylate is the most important intermediate during production of Vandetanib.

Bond lengths and angles of the title compound are within normal ranges [7]. The crystal structure analysis of the title compound revealed that the 3 rings: piperidine ring (C16—C17—C18—C19—C20—N4), quinazoline ring (C2—N2—C1—N1—C4—C5—C6—C7—C8—C3) and 4-bromo-2-fluorophenyl ring (C9—C10—C11—C12—C13—C14), are not coplanar. The dihedral angle between the plane of the 4-bromo-2-fluorophenyl ring and the best plane of the piperidine ring is 33.9(2)°. The dihedral angle between the quinazolinyl moiety and the best plane of the piperidine ring is 32.7(2)°. In the crystal of the title compound, there are weak C—H⋯O, C—H⋯N and N—H⋯F intramolecular hydrogen bonds. There may be some π-π stacking interactions, as the centroid to centroid distance between the nearest rings is less than 5 Å.

Acknowledgement

We thank the Center of Testing and Analysis, Nanjing University.

References

Enraf-Nonius: CAD-4 Software. Enraf-Nonius, Delft, The Netherlands, (1985).Suche in Google Scholar

Harms, K.; Wocadlo, S.: XCAD4. University of Marburg, Germany, (1995).Suche in Google Scholar

Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Suche in Google Scholar PubMed

Spek, A. L.: Single-crystal structure validation with the program PLATON. J. Appl. Crystallogr. 36 (2003) 7–13.10.1107/S0021889802022112Suche in Google Scholar

Gant, T. G.; Sarshar, S.; Shahbaz, M.: Substituted quinazoline inhibitors of growth factor receptor tyrosine kinases. Patent: WO 2010/028254 A2.Suche in Google Scholar

Regalbuto, C.; Frasca, F.; Pellegriti, G.: Update on thyroid cancer treatment. Future Oncology 8 (2012) 1331–1348.10.2217/fon.12.123Suche in Google Scholar PubMed

Allen, F. H.; Kennard, O.; Watson, D. G.; Brammer, L.; Orpen, A. G.; Taylor, R.: Tables of bond lengths determined by X-ray and neutron diffraction. Part 1. Bond lengths in organic compounds. J. Chem. Soc. Perkin Trans. 2 (1987) S1–S19.10.1039/p298700000s1Suche in Google Scholar

Received: 2017-2-10
Accepted: 2017-6-27
Published Online: 2017-7-14
Published in Print: 2017-9-26

©2017 Kai Wang et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Artikel in diesem Heft

  1. Cover and Frontmatter
  2. Crystal structure of 2-(2-ethoxyphenyl)-7-propyl-5-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one, C17H20N4O2
  3. Crystal structure of catena-poly[aqua-(μ3-1,3,5-benzenetricarboxylato-κ3O:O′:O′′)-[μ3hydroxy-(1,3-di-(μ2-1,2,4-triazole-4-yl)benzoato-κ2N:N′)copper(II)], C19H16Cu2N6O9
  4. Crystal structure of poly[aqua-(μ3-3,5-di(4H-1,2,4-triazolyl-4-κ3N,N′:N′′)benzenecarboxylato)silver(I)], C11H9AgN6O3
  5. Crystal structure of tetrapropylammonium hydrogen carbonate, C13H29NO3
  6. Crystal structure of poly[μ2-acetato-κ3-O,O′:O′)diaqua(μ3-isophthalato-κ4O,O′:O′′:O′′′)yttrium(III)] monohydrate, C20H24O17Y2
  7. Crystal structure of catena-poly[dichlorido-(μ2-4-(1H-pyrazol-3-yl)-pyridine-κ2N,N′)]cadmium(II), C48H42Cd3Cl16N18
  8. Crystal structure of bis(tetraethylammonium) [1,1′-biphenyl]-2,2′-dicarboxylate trihydrate, C30H54N2O7
  9. Crystal structure of poly[(thiophene-3,4-dicarboxylato-κ1O)bis[1,2-bis(4-pyridyl)ethane-κ2N:N′]silver(I)] octahydrate, C30H42Ag2N4O12S
  10. The crystal structure of amine-(4-(1H-1,2,4-triazol-1-yl)benzoato-κN)silver(I) dihydrate, C9H13AgN4O4
  11. Crystal structure of poly[tetrakis(μ2-cyanido-κ2N:O)-cyanido-tris(pyridine)dicobalt(II/III)], C20H15Co2N8
  12. Crystal structure of bis(pyridine)-bis(2-formyl-4,6-dichlorophenolato)cobalt(II), C24H16Cl4CoN2O4
  13. Crystal structure of (E)-1-(4-(((E)-5-bromo-2-hydroxybenzylidene)amino)phenyl)ethan-1-one O-methyl oxime, C16H15BrN2O2
  14. Crystal structure of catena-poly[(μ2-3-(1H-pyrazol-4-yl)-5-(pyridin-4-yl)-1,2,4-triazole-κ N:N′)-bis(benzoato-κO)zinc(II)], C24H18N6O4Zn
  15. Hydrothermal synthesis and crystal structure of a poly[aqua-(μ4-4-(carboxylatomethyl)benzoato-κ4O:O′:O′′:O′′′)-(μ2-1-(4-(1H-imidazol-1-yl)benzyl)-1H-1,2,4-triazole-κ2N:N′) dimanganese(II)], [Mn2(C9H6O4)2(C12H11N5)(H2O)]
  16. Crystal structure of diaqua-catena-poly[diaqua-bis(μ2-5-(4-(1H-1,2,4-triazol-1-yl)phenyl)tetrazol-2-ido-κ2N:N′)cobalt(II)] dihydrate, C20H24CoN14O4
  17. Crystal structure of bis(μ3-2,2′-azanediylbis(ethan-1-olato)-κ5O:O,N,O′:O′)-tetrachlorido-bis(μ2-2-((2-hydroxyethyl)amino)ethan-1-olato-κ3N,O:O)dicobalt(II)dicobalt(III), C16H38Cl4Co4N4O8
  18. Crystal structure of poly[μ4-(4-(carboxylatomethyl)benzoato-κ4O:O′:O′′:O′′′)-(2-(4-(1H-imidazol-1-yl)phenyl)-1H-benzo[d]imidazole-κN)manganese(II)] [Mn(C9H6O4)(C16H12N4)]
  19. Crystal structure of 4-chloro-6-phenylpyrimidine, C10H7ClN2
  20. The crystal structure of [6-methoxy-2-(2,2,2-trifluoroacetyl)-3,4-dihydronaphthalen-1(2H)-one]difluoroborane, C13H10BF5O3
  21. Crystal structure of 3,3′-(butane-1,4-diylbis(azanylylidene))bis(1-phenylbut-1-en-1-olato)-κ4N,N′,O,O′]copper(II), C24H26N2O2Cu
  22. Crystal structure of tetraaqua-bis((E)-N′-(2-bromobenzylidene)isonicotinohydrazide-κN)zinc(II) dinitrate, C26H28N8O12Br2Zn
  23. Crystal structure of 2-amino-4-(4-bromophenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C16H13BrN2O2
  24. A single crystal study on tert-butyl-4-((4-(4-bromo-2-fluorophenylamino)-6-methoxyquinazolin-7-yloxy)methyl)piperidine-1-carboxylate, C26H30BrFN4O4
  25. Crystal structure of 1,1′-((1E,1′E)-(((ethane-1,2-diylbis(oxy))bis(2,1-phenylene))bis(azanylylidene))bis(methanylylidene))bis(naphthalen-2-olato-κ3O,O′,N)zinc(II), C36H26N2O4Zn
  26. Crystal structure of diaqua-bis(5′-(pyridin-1-ium-4-yl)-1H-[3,3′-bi(1,2,4-triazol)]-2′-ide-κ2N,N′)cobalt(II) — bis(5-(pyridin-4-yl-κN)-1H,1′H-3,3′-bi(1,2,4-triazole))octamolybdate – water (2/1/8), C27H33CoMo4N21O19
  27. Crystal structure of 3-cyclohexyl-2-(cyclohexylimino)-2,3-dihydro-6,8-diiodo-4H-1,3-benzoxazin-4-one, C20H24I2N2O2
  28. Crystal structure of dinitrato-κO-bis(tris((1H-benzo[d]imidazol-2-yl)methyl)amine-κ4N,N′,N′′,N′′′)-(μ2-cyclohexane-1,4-dicarboxylato-κ4O,O′:O′′,O′′′)dimanganese(II) – methanol – water (1/6/2), C62H80Mn2N16O18
  29. Crystal structure of bis(2-hydroxyethyl(phenyl)carbamodithioate)nickel(II), C18H20N2NiO2S4
  30. Crystal structure of methyl 1-(4-fluorobenzyl)-4-methoxy-5-oxopyrrolidine-3-carboxylate, C14H16FNO4
  31. Crystal structure of di-μ-iodido-bis(6-(p-tolyl)-2,2′-bipyridine-κ2N,N′)dicopper(I) — 2-(diphenylphosphoryl)benzoic acid (1/2), C36H29CuIN2O3P
  32. Crystal structure of 2-amino-4-(3-bromo-4-fluoro-phenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C18H16BrFN2O2
  33. Crystal structure of bis(μ2-2-chlorobenzoato-κ3O,O′:O′)-(2-chlorobenzoato-κO)-(2-chlorobenzoato-κO,O′)-bis(1,10-phenanthroline-κ2N,N′)-dicadmium(II) monohydrate, C52H36Cd2Cl4N4O10
  34. Crystal structure of 2-(8a-methyl-5-oxo-hexahydroimidazo [1,2-a]pyridin-1(5H)-yl)-2-oxoethyl acetate, C12H18N2O4
  35. Crystal structure of (E)-N,N-diethyl-2-(5-nitrothiazol-2-yl)-1-phenylethen-1-amine, C15H17N3O2S
  36. Crystal structure of diazido-dimethanolato-bis(μ2-2-(((3-oxidopropyl)imino)methyl)phenolato-κ4O:O,O′,N)dimanganese(III), C22H28Mn2N8O6
  37. The crystal structure of bis(2-(2,2,2-trifluoroacetyl)-3,4-dihydronaphthalen-1-olato-κ2O,O′)copper(II), C24H16CuF6O4
  38. Crystal structure of hexaaquanickel(II) bis((E)-4-((4-(dimethylamino)phenyl)diazenyl)benzenesulfonate), C28H40N6NiO12S2
  39. Crystal structure of catena-poly[aqua-(μ2-hexamethylenetetramine-κ2N:N′)-bis(2,6-difluorobenzoato-κ2O:O′)cadmium(II)]monohydrate, C20H22CdF4N4O6
  40. Crystal structure of 3-benzyl-2,3-dihydro-2-thioxoquinazolin-4(1H)-one, C15H12N2OS
  41. Crystal structure of bis(μ2-ferrocenecarboxylato-κ2O:O′)-bis(1,10-phenanthroline-κ2N,N′)-(μ2-methanolato2O,O)dicopper(II) tetrafluoroborate – acetonitrile (1/1), C49H40BCu2F4Fe2N5O5
  42. The crystal structure of tetrakis(1,3,5-triaza-7-phosphatricyclo[3.3.1.13,7]decane-κP)silver(I) chloride dihydrate, C24H60AgClN12O6P4
  43. Crystal structure of 5-ethyl-2-(p-tolyl)-1,3-dioxane-5-carboxylic acid, C14H18O4
  44. Crystal structure of 2-(4-fluorophenyl)-1,3-dimethyl-1H-perimidin-3-ium iodide, C19H16ClIN2
  45. Crystal structure of catena-poly[(μ2-hexamethylenetetramine-κ2N:N′)-tetrakis(μ2-2,6-difluorobenzoato-κ2O:O′)dicopper(II)], C34H24Cu2F8N4O8
  46. Crystal structure of ethyl 3-hydroxy-5-methyl-2-(4-(m-tolyl)-1H-1,2,3-triazol-1-yl)-[1,1′-biphenyl]-4- carboxylate, C25H24N3O3
  47. The crystal structure of carbonyl(2-oxopyridin-1(2H)-olato-κ2O,O′)-(diphenylcyclohexylphosphine-κP)rhodium(I), C24H25NO3PRh
  48. Crystal structure of bis((pyrazin-2-ylmethyl)(pyrazine-2-carbonyl)amido-κ3N,N′,N′′)copper(II), C20H16CuN10O2
  49. Crystal structure of catena-poly[tetraaqua-(μ2-succinonitrile-κ2N:N′)cobalt(II)] dinitrate, C4H12CoN4O10
  50. The crystal structure of 1,1′-bisisoquinoline, C18H12N2
  51. Crystal structure of bis(hydroxydi(pyridin-2-yl)methanolato-κ3N,N′,O)cobalt(III) perchlorate dihydrate, C22H22ClCoN4O10
Heruntergeladen am 5.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2017-0024/html
Button zum nach oben scrollen